DSCI: Level 3, Full Text Screening Form for Key Questions 1 to 4

PLEASE NOTE THE FOLLOWING:

If you have excluded a record for eligibility for KQ 1-4 (as stated with a response of 'No' to any of questions 1-5), please respond to the remaining unanswered questions 1-5 with 'NO RESPONSE - EXCLUDED IN OTHER QUESTION' and respond to question 6 accordingly. You must respond to all questions for each record.

1. Relevant INTERVENTION/EXPOSURE(S) and COMPARATOR(S) (see footnotes 1 & 2)**?**

- **Relevant dietary supplement VS. no dietary supplement** (e.g. no treatment or placebo) **OR**
- **Relevant dietary supplement VS. other relevant dietary supplement**

❑ Yes (Please specify [name] dietary supplement(s) - if many [e.g. review] state 'mixed')

_____

❑ No - no supplement or no appropriate comparator (EXCLUDE)

❑ Details present but content expertise requested (please describe)

_____

❑ NO RESPONSE - EXCLUDED IN OTHER QUESTION

❑ No - non-relevant supplement and/or comparator (please state) (EXCLUDE)

_____

2. Full study, subgroup results or regression analysis in relevant POPULATION for KQ 1-4**?**

- **Adults (majority ≥ 16 years old) taking one or more specific cardiovascular drugs or class of cardiovascular drugs commonly used in outpatient setting** (see footnote 3)

❑ Yes (Please state which CVD(s) or which class(es) of CVD)

_____

❑ No or unclear (specific CVD(s) or class(es) of CVDs not explicit) (EXCLUDE)

❑ Details available but content expertise requested (please describe)

❑ _____

❑ NO RESPONSE – EXCLUDED IN OTHER QUESTION

3. Relevant STUDY DESIGN?

- **Systematic review meeting minimum eligibility requirements** (see footnote 4) **OR**
- **Experimental or observational comparative study** (RCT, non-RCT, cohort, case-control, cross-sectional) **with independent (concurrent or historical) control group** including at least 5 participants.

❑ Yes - Systematic review meeting minimum criteria for review eligibility (see footnote 3)

❑ Yes - Experimental or observational comparative study with independent control and at least 5 participants

❑ No - likely a RELEVANT, THOROUGH (w.r.t. search methods) systematic review but does NOT meet minimum criteria for review eligibility (EXCLUDE)

- ❑ No - experimental study without independent control (before and after study)
- ❑ None of the above (EXCLUDE)
- ❑ NO RESPONSE - EXCLUDED IN OTHER QUESTION

4. Relevant OUTCOME(S) for at least one of Key questions 1-4**?**

- KQ 1: Clinical efficacy/effectivess cardiovascular outcomes
- KQ 2: Intermediate efficacy/effectivess cardiovascular outcomes
- KQ 3: Clinical or intermediate harms outcomes
- KQ 4: Pharmacokinetic/pharmacodynamic outcomes

Note: for list of relevant outcomes, please see review protocol

- ❑ Yes
- ❑ No (EXCLUDE)
- ❑ NO RESPONSE - EXCLUDED IN OTHER QUESTION

5. Relevant LANGUAGE?

- **SR** published in **English**
- **Experimental or observational comparative study** published in **English or German**

- ❑ Yes - SR in English
- ❑ Yes - Exp/Obs study in English
- ❑ Yes - Exp/Obs study in German
- ❑ No - SR in other language (please state which)

  _____
- ❑ No - Exp/Obs study in other language (please state which)

  _____
- ❑ NO RESPONSE - EXCLUDED IN OTHER QUESTION

6. Does this report include Mix of CVD drugs that are used by <80% of the population or the % of patients using CVD drugs are not described? (Such studies will not be used in the evidence synthesis of the report--May 16)

- ❑ Yes (please describe)

  _____
- ❑ No